Stock BCDA BIOCARDIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioCardia, Inc.

Equities

BCDA

US09060U5074

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.3766 USD +2.34% Intraday chart for BioCardia, Inc. +4.61% -43.30%
Apr. 25 BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort CI
Mar. 27 Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024

Business Summary

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

Number of employees: 18

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
1 100.0 % 0 100.0 % -64.72%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 0 100.0 % -64.72%

Managers

Managers TitleAgeSince
Peter Altman CEO
 Chief Executive Officer 57 01-12-31
David McClung DFI
 Director of Finance/CFO 61 13-08-31
Debby Holmes-Higgin CTO
 Chief Tech/Sci/R&D Officer - 17-07-31
Sujith Shetty CTO
 Chief Tech/Sci/R&D Officer - 19-02-28
Ian McNiece CTO
 Chief Tech/Sci/R&D Officer 70 17-11-07
Anne Laluc IRO
 Public Communications Contact - -
Mark Schwartz PRN
 Corporate Officer/Principal - 18-10-31
Edward Gillis PRN
 Corporate Officer/Principal 62 19-12-31

Members of the board

Members of the board TitleAgeSince
Simon Stertzer BRD
 Director/Board Member 88 01-12-31
Jay Moyes BRD
 Director/Board Member 70 10-12-31
Richard Krasno BRD
 Director/Board Member 82 16-10-23
William M. Facteau BRD
 Director/Board Member 53 23-10-17
Peter Altman CEO
 Chief Executive Officer 57 01-12-31
Andrew Blank CHM
 Chairman 68 19-09-30
Jim Allen BRD
 Director/Board Member 69 19-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,867,520 17,772,649 ( 66.15 %) 0 66.15 %

Shareholders

NameEquities%Valuation
Simon Stertzer
5.749 %
1,489,754 5.749 % 606 330 $
Phillip Frost
4.964 %
1,286,454 4.964 % 523 587 $
Joseph Daly
4.484 %
1,162,077 4.484 % 472 965 $
EssigPR, Inc.
4.089 %
1,059,540 4.089 % 431 233 $
Gerald P Peters
3.759 %
974,073 3.759 % 396 448 $
Jim Allen
3.454 %
894,927 3.454 % 364 235 $
CM Management LLC
2.701 %
700,000 2.701 % 284 900 $
Vanguard Global Advisers LLC
2.511 %
650,763 2.511 % 264 861 $
Peter Altman
2.156 %
558,697 2.156 % 227 390 $
Andrew Blank
1.941 %
503,063 1.941 % 204 747 $
NameEquities%Valuation
Citadel Securities GP LLC
-
79,562 - 1 193 $
Securities America Advisors, Inc.
-
51,963 - 779 $
GenTrust LLC
-
15,293 - 229 $
Merrill Lynch, Pierce, Fenner & Smith, Inc.
-
12,279 - 184 $
UBS Securities LLC
-
1 - 0 $

Company contact information

BioCardia, Inc.

320 Soquel Way

94085, Sunnyvale

+

http://www.biocardia.com
address BioCardia, Inc.(BCDA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for BioCardia, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3766 USD
Average target price
4 USD
Spread / Average Target
+962.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOCARDIA, INC. Stock BioCardia, Inc.
-43.30% 10.12M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BCDA Stock
  4. Company BioCardia, Inc.